TAHIRA QURESHI: Open Payments
NPI 1114400629 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,564 in 49 payments from 16 companies in 2025. Trend: 2023 $2,178 · 2024 $1,492 · 2025 $1,564
Food & beverage: $1,564
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $696 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $149 |
| Novo Nordisk Inc | 1 | $119 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $89 |
| ABBVIE INC. | 4 | $79 |
| Lilly USA, LLC | 3 | $69 |
| Corcept Therapeutics | 3 | $48 |
| Abbott Laboratories | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
Products named: FARXIGA, Kerendia, Ozempic, JARDIANCE, XIFAXAN, BREZTRI, UBRELVY, Korlym.
Industry payments across FL — which companies pay providers there.
